176 related articles for article (PubMed ID: 10589007)
21. Immunoglobulin G4-antibodies to rBet v 1 and risk of sensitization and atopic disease in the child.
Kihlström A; Hedlin G; Pershagen G; Troye-Blomberg M; Härfast B; Lilja G
Clin Exp Allergy; 2005 Dec; 35(12):1542-9. PubMed ID: 16393319
[TBL] [Abstract][Full Text] [Related]
22. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy.
Kinaciyan T; Nagl B; Faustmann S; Frommlet F; Kopp S; Wolkersdorfer M; Wöhrl S; Bastl K; Huber H; Berger U; Bohle B
J Allergy Clin Immunol; 2018 Mar; 141(3):1002-1008. PubMed ID: 28870463
[TBL] [Abstract][Full Text] [Related]
24. Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild-type in patients with allergic rhinitis.
van Hage-Hamsten M; Johansson E; Roquet A; Peterson C; Andersson M; Greiff L; Vrtala S; Valenta R; Grönneberg R
Clin Exp Allergy; 2002 Oct; 32(10):1448-53. PubMed ID: 12372124
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
[TBL] [Abstract][Full Text] [Related]
26. New Bet v 1 isoforms including a naturally occurring truncated form of the protein derived from Austrian birch pollen.
Friedl-Hajek R; Radauer C; O'Riordain G; Hoffmann-Sommergruber K; Leberl K; Scheiner O; Breiteneder H
Mol Immunol; 1999 Jul; 36(10):639-45. PubMed ID: 10509815
[TBL] [Abstract][Full Text] [Related]
27. How far can we simplify in vitro diagnostics for Fagales tree pollen allergy? A study with three whole pollen extracts and purified natural and recombinant allergens.
Van Ree R; Van Leeuwen WA; Akkerdaas JH; Aalberse RC
Clin Exp Allergy; 1999 Jun; 29(6):848-55. PubMed ID: 10336603
[TBL] [Abstract][Full Text] [Related]
28. Component-resolved diagnosis (CRD) of type I allergy with recombinant grass and tree pollen allergens by skin testing.
Heiss S; Mahler V; Steiner R; Spitzauer S; Schweiger C; Kraft D; Valenta R
J Invest Dermatol; 1999 Nov; 113(5):830-7. PubMed ID: 10571741
[TBL] [Abstract][Full Text] [Related]
29. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.
Siebeneicher S; Reuter S; Wangorsch A; Krause M; Foetisch K; Heinz A; Naito S; Reuter A; Taube C; Vieths S; Scheurer S; Toda M
Allergy; 2015 Dec; 70(12):1559-68. PubMed ID: 26304061
[TBL] [Abstract][Full Text] [Related]
30. Isoforms of atopic allergens with reduced allergenicity but conserved T cell antigenicity: possible use for specific immunotherapy.
Ferreira F; Hirthenlehner K; Briza P; Breiteneder H; Scheiner O; Kraft D; Breitenbach M; Ebner C
Int Arch Allergy Immunol; 1997; 113(1-3):125-7. PubMed ID: 9130500
[TBL] [Abstract][Full Text] [Related]
31. Cross-reacting allergens in tree pollen and pollen-related food allergy: implications for diagnosis of specific IgE.
Scheiner O; Aberer W; Ebner C; Ferreira F; Hoffmann-Sommergruber K; Hsieh LS; Kraft D; Sowka S; Vanek-Krebitz M; Breiteneder H
Int Arch Allergy Immunol; 1997; 113(1-3):105-8. PubMed ID: 9130495
[TBL] [Abstract][Full Text] [Related]
32. Biological and immunological importance of Bet v 1 isoforms.
Breitenbach M; Ferreira F; Jilek A; Swoboda I; Ebner C; Hoffmann-Sommergruber K; Briza P; Scheiner O; Kraft D
Adv Exp Med Biol; 1996; 409():117-26. PubMed ID: 9095231
[TBL] [Abstract][Full Text] [Related]
33. Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001.
Smole U; Balazs N; Hoffmann-Sommergruber K; Radauer C; Hafner C; Wallner M; Ferreira F; Grössinger R; de Jong EC; Wagner S; Breiteneder H
Immunobiology; 2010 Nov; 215(11):903-9. PubMed ID: 20005001
[TBL] [Abstract][Full Text] [Related]
34. Rapid production of the major birch pollen allergen Bet v 1 in Nicotiana benthamiana plants and its immunological in vitro and in vivo characterization.
Krebitz M; Wiedermann U; Essl D; Steinkellner H; Wagner B; Turpen TH; Ebner C; Scheiner O; Breiteneder H
FASEB J; 2000 Jul; 14(10):1279-88. PubMed ID: 10877820
[TBL] [Abstract][Full Text] [Related]
35. Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1- related PR-10 protein in soybean, SAM22.
Kleine-Tebbe J; Vogel L; Crowell DN; Haustein UF; Vieths S
J Allergy Clin Immunol; 2002 Nov; 110(5):797-804. PubMed ID: 12417891
[TBL] [Abstract][Full Text] [Related]
36. Bet v 1, the major birch pollen allergen, and Mal d 1, the major apple allergen, cross-react at the level of allergen-specific T helper cells.
Fritsch R; Bohle B; Vollmann U; Wiedermann U; Jahn-Schmid B; Krebitz M; Breiteneder H; Kraft D; Ebner C
J Allergy Clin Immunol; 1998 Oct; 102(4 Pt 1):679-86. PubMed ID: 9802379
[TBL] [Abstract][Full Text] [Related]
37. Molecular composition and biological activity of commercial birch pollen allergen extracts.
Focke M; Marth K; Valenta R
Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
[TBL] [Abstract][Full Text] [Related]
38. Different profiles in specific IgE to rBet v 1 and rBet v 2 in patients allergic to birch pollen from six countries.
Elfman L; Svensson M; Lidholm J; Pauli G; Valenta R
Int Arch Allergy Immunol; 1997; 113(1-3):249-51. PubMed ID: 9130537
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma.
Tourdot S; Airouche S; Berjont N; Moussu H; Betbeder D; Nony E; Bordas-Le Floch V; Baron-Bodo V; Mascarell L; Moingeon P
Vaccine; 2013 May; 31(23):2628-37. PubMed ID: 23583462
[TBL] [Abstract][Full Text] [Related]
40. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System.
Movérare R; Elfman L; Vesterinen E; Metso T; Haahtela T
Allergy; 2002 May; 57(5):423-30. PubMed ID: 11972482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
